ClinicalTrials.gg
RecruitingNCT06878729ADRENALINEUpdated Jan 2, 2026

Antegrade Dissection and Re-entry Versus Retrograde Strategy in CTO PCI

An interventional study of CTO PCI using ADR strategy and CTO PCI using retrograde strategy in Coronary Artery Disease, Coronary Occlusion and Percutaneous Coronary Intervention, sponsored by National Institute of Cardiology, Warsaw, Poland. Recruiting at 3 sites in Poland. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-01-02.

Sponsored by National Institute of Cardiology, Warsaw, Poland · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Jul 2025; still recruiting 1 year 3 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
74
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 18 studies in Coronary Artery Disease by National Institute of Cardiology, Warsaw, Poland — 5 open to participants now, 5 under way, none of them phase 3. Coronary Artery Disease · National Institute of Cardiology, Warsaw, Poland.

Planned enrollment
7th of 12
74 · median 97
Started
2025
with 2 others
No phase
9 of 18
3 open now
Registered
16th of 18
by date

Among the 18 studies in Coronary Artery Disease by National Institute of Cardiology, Warsaw, Poland, this one is the 7th largest by planned enrollment of the 12 interventional ones that give a count, is one of 3 that started in 2025, is one of 9 with no phase, and was the 16th registered.

Coronary Artery Disease

4,866 studies on the registry are indexed under Coronary Artery Disease; 892 are open to participants now.

Browse Coronary Artery Disease studies →

Open to participants now

5 of the 18 studies in Coronary Artery Disease by National Institute of Cardiology, Warsaw, Poland are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

Who these studies take

Of the 591 Coronary Artery Disease studies recruiting now, 404 (68%) set no upper age limit and 68 (12%) stop at 75 or younger; 37 take children under 18; 49 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 18 studies in Coronary Artery Disease by National Institute of Cardiology, Warsaw, Poland, or all of them as a file.
02

Study summary

The ADRENALINE trial has been designed as a multi-center, prospective randomized study to compare the procedural and periprocedural outcomes of coronary chronic total occlusion (CTO) percutaneous coronary intervention (PCI) using antegrade dissection and re-entry (ADR) versus retrograde strategy. Beyond the patient-oriented outcomes, the influence of the studied CTO PCI strategies on the stress levels among interventional cardiologists will be explored.

The main questions it aims to answer are as follows:

  • What is the difference between ADR versus retrograde strategy with regard to total procedure time, the rates of successful guidewire crossing and periprocedural complications as well as stress levels experienced by interventional cardiologists?
  • Is retrograde approach associated with higher rates of myocardial injury/infarction based on cardiac troponin/cardiac magnetic resonance (CMR) as compared with ADR?

Participants will undergo pre- and postprocedural laboratory testing (cardiac troponin, CK-MB), CMR for late gadolinium enhancement and health status assessment. Subjects undergoing successful CTO PCI using antegrade wiring strategy will be included in the observational arm.

Read the detailed description

The ADRENALINE trial is planned as a multicenter, prospective randomized research experiment in patients with clinical indication for PCI of CTO. The target population will comprise patients with at least difficult CTO (J-CTO score ≥2) and angiographic equipoise for either ADR or the retrograde CTO recanalization strategy as evaluated by 2 independent CTO PCI operators. The pre-procedural assessment will comprise cardiac magnetic resonance (CMR) for late gadolinium enhancement, laboratory testing (cardiac troponin, creatine kinase-MB) and health status assessed by the Seattle angina questionnaire (SAQ) and the Rose Dyspnea Scale. Subsequently patients with either failed or unattempted primary antegrade wiring strategy will be evenly randomized (1:1 fashion) to either ADR or the retrograde CTO crossing strategy (n=74), while subjects undergoing successful antegrade wiring will be included in the observational arm (n=47). After CTO PCI, the cardiac troponin and creatine kinase-MB will be measured at 12 hours intervals (at least up to 24 hours), while CMR with late gadolinium enhancement will be repeated within 5 days post-procedure (including the observational arm). The health status of the study participants (SAQ and the Rose Dyspnea Scale) will be re-assessed at 3-months post-CTO PCI. In addition, to investigate the effect of the studied CTO PCI strategies on the occupational hazard of interventional cardiologists, the physical and mental stress levels experienced by CTO operators will be continuously monitored during the procedure. The co-primary endpoint is defined as: 1) total procedure time and 2) successful guidewire crossing through CTO. The secondary endpoints include: time of successful guidewire crossing through CTO, final technical success of CTO PCI, radiation dose, contrast volume, equipment cost, procedural complications, rate of periprocedural myocardial injury, rate of new myocardial infarction on CMR, quality of life, target lesion failure (cardiac death, target vessel-related myocardial infarction, and clinically-driven target lesion revascularization) at 3 months follow-up, and stress indices experienced by physicians during the procedure.

03

Conditions studied

  • Coronary Artery Disease
  • Coronary Occlusion
  • Percutaneous Coronary Intervention

Keywords

  • coronary artery disease
  • percutaneous coronary intervention
  • coronary chronic total occlusion
  • antegrade dissection and re-entry
  • retrograde strategy
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • clinical indication for CTO PCI as determined by the local heart team (presence of angina or equivalent symptoms and/or documented ischemia or viability)
  • at least difficult native CTO lesion with J-CTO difficulty score ≥2 points on invasive angiography
  • angiographic suitability for both ADR and the retrograde strategy as assessed by 2 independent hybrid CTO PCI operators
  • for participation in the study

Exclusion criteria

Exclusion Criteria:

  • \<18 years of age
  • acute myocardial infarction
  • cardiogenic shock
  • severe valvular disease
  • estimated \<1 year
  • to PCI
  • contrast allergy
  • positive pregnancy test or breast-feeding
  • native CTO lesion with easy or intermediate difficulty score on invasive angiography (J-CTO score \<2 points)
  • lack of angiographic equipoise between the ADR and the retrograde strategy as assessed by 2 independent hybrid CTO PCI operators
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
74 participants (estimated)

Study arms

  • Other
    ADR strategy

    Patients with either failed or unattempted primary antegrade wiring strategy will be evenly randomized (1:1 fashion) to either ADR or retrograde CTO crossing strategy. The ADR, as part of the antegrade approach, involves extraplaque crossing of the occluded coronary artery with subsequent reentry into the distal true lumen using dedicated reentry systems or knuckle wire techniques.

    Procedure: CTO PCI using ADR strategy

  • Other
    Retrograde strategy

    Patients with either failed or unattempted primary antegrade wiring strategy will be evenly randomized (1:1 fashion) to either ADR or retrograde CTO crossing strategy. The retrograde technique, planned as the comparator to the ADR strategy, relies on crossing the occluded coronary artery from the distal vessel (i.e. against the original direction of blood flow). Retrograde CTO crossing is attempted either with retrograde intraplaque wiring or more frequently using the retrograde dissection and reentry techniques.

    Procedure: CTO PCI using retrograde strategy

Interventions

  • ProcedureCTO PCI using ADR strategy

    CTO recanalization using ADR performed as primary or secondary CTO PCI strategy (i.e. in case of unattempted or failed antegrade wiring, respectively).

  • ProcedureCTO PCI using retrograde strategy

    CTO recanalization using retrograde approach performed as primary or secondary CTO PCI strategy (i.e. in case of unattempted or failed antegrade wiring, respectively).

06

What researchers measure

Primary outcomes

  1. Total procedure time

    Total procedure time in minutes.

    Time frame: procedural (1 day)

  2. Successful guidewire crossing through CTO

    Rate of successful guidewire crossing through CTO.

    Time frame: procedural (1 day)

Secondary outcomes

  1. Technical success

    Achievement of Thrombolysis In Myocardial Infarction grade 3 flow in all ≥2.5-mm distal branches with \<30% residual stenosis.

    Time frame: procedural (1 day)

  2. Time of successful guidewire crossing

    Time of successful guidewire crossing through CTO in minutes defined as the time from starting ADR or the retrograde approach to the time of successful CTO recanalization using any technique.

    Time frame: procedural (1 day)

  3. Fluoroscopy time

    Fluoroscopy time in minutes.

    Time frame: procedural (1 day)

  4. Radiation dose

    Total radiation dose in Gy and mGycm2.

    Time frame: procedural (1 day)

  5. Contrast volume

    Total contrast volume in mL.

    Time frame: procedural (1 day)

  6. Cost of CTO PCI

    Total cost of CTO PCI procedure in PLN.

    Time frame: procedural (1 day)

  7. Number and type of procedural complications

    Total number and specification of procedural complications (death, non-fatal myocardial infarction, cardiac tamponade requiring pericardiocentesis, coronary perforation, stroke, major bleeding according to Bleeding Academic Research Consortium).

    Time frame: procedural (1 day)

  8. Periprocedural myocardial injury

    Any periprocedural myocardial injury based on the dynamics of cardiac troponin.

    Time frame: in-hospital (2-5 days)

  9. Periprocedural myocardial infarction

    Any periprocedural myocardial infarction based on the dynamics of creatine kinase-MB/cardiac troponin and according to Fourth universal definition of myocardial infarction.

    Time frame: in-hospital (2-5 days)

  10. Myocardial infarction on CMR

    Any new myocardial infarction as assessed on serial CMR with late gadolinium enhancement.

    Time frame: in-hospital (2-5 days)

  11. Target lesion failure

    Total number of cardiac death, target vessel-related myocardial infarction or clinically-driven target lesion revascularization.

    Time frame: 3-months

  12. All-cause death

    Any death observed.

    Time frame: 3-months

  13. Cardiac death

    Any cardiac death observed.

    Time frame: 3-months

  14. Target vessel-related myocardial infarction

    Any target vessel-related myocardial infarction observed.

    Time frame: 3-months

  15. Clinically-driven target lesion revascularization

    Any clinically-driven target lesion revascularization observed.

    Time frame: 3-months

  16. CCS class

    Quality of life assessed by the Canadian Cardiovascular Society (CCS) grading scale measuring the severity of exertional angina (it uses a scale from 1 to 4 where 1 means angina only occurs with strenuous, rapid or prolonged exertion, and 4 means angina is present at rest).

    Time frame: 3-months

  17. SAQ score

    Quality of life assessed by the Seattle Angina Questionnaire comprising a 19-item questionnaire categorized into five scales (angina frequency, angina stability, physical limitations, treatment satisfaction, and disease-specific quality of life) with each scale transformed to a 0-100 score (the higher the score, the better the quality of life).

    Time frame: 3-months

  18. Dyspnea severity on the Rose Dyspnea Scale

    Quality of life assessed by the Rose dyspnea scale questionnaire measuring dyspnea complaints or shortness of breath (it consists of a score from 0 to 4, where 0 means no dyspnea complaints and 4 means the patient has complaints during no or minimal physical effort).

    Time frame: 3-months

  19. Heart rate

    Mean heart rate of the first CTO operator throughout CTO PCI.

    Time frame: operator-related (1 day)

  20. Mean arterial pressure

    Mean arterial pressure in mmHg of the first CTO operator throughout CTO PCI.

    Time frame: operator-related (1 day)

  21. Systolic blood pressure

    Mean systolic blood pressure in mmHg of the first CTO operator throughout CTO PCI.

    Time frame: operator-related (1 day)

  22. Diastolic blood pressure

    Mean diastolic blood pressure in mmHg of the first CTO operator throughout CTO PCI.

    Time frame: operator-related (1 day)

  23. Blood glucose concentration

    Continuous blood glucose concentration monitoring in mmol/l of the first CTO operator throughout CTO PCI.

    Time frame: operator-related (1 day)

  24. Brain activity monitoring

    Continuous brain activity monitoring via quantitative near infrared spectroscopy system assessing changes in relative concentrations of oxygenated and deoxygenated hemoglobin of the frontal cortex of the first CTO operator throughout CTO PCI.

    Time frame: operator-related (1 day)

  25. Salivary cortisol concentration

    Salivary cortisol concentration in ng/mL of the first CTO operator measured at 30-min intervals throughout CTO PCI.

    Time frame: operator-related (1 day)

  26. High-sensitivity cardiac troponin concentration

    Changes in the blood concentration of the high-sensitivity cardiac troponin (ng/L) pre- and post-CTO PCI in the first CTO operator.

    Time frame: operator-related (1 day)

  27. Perceived Stress Scale score

    Stress level assessment in the first CTO operator adapted to CTO procedure and based on the Perceived Stress Scale score containing 10 questions with a 5-point answer scale ranging from 0 ('never') to 4 ('very often') - the minimum score is 0 (indicating no stress) and the maximum score is 40 (indicating the highest level of stress).

    Time frame: operator-related (1 day)

07

Study locations

3 of 3 sites recruiting
08

References and documents

Publications

  • Opolski MP, Spiewak M, Machaj F, Borzuta H, Sobieszek G, Drozd J, Kiljanski F, Matsko P, Klopotowski M, Zieba B, Kula W, Marczak M, Debski A, Witkowski A, Knaapen P, Leibundgut G, Ungureanu C, Rinfret S, Brilakis ES. Antegrade dissection and re-entry versus retrograde strategy in chronic total occlusion percutaneous coronary intervention: Rationale and design of the ADRENALINE randomized study. Am Heart J. 2026 Jul 11:107538. doi: 10.1016/j.ahj.2026.107538. Online ahead of print. PubMed 42436000 ↗
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2025 (actual). Primary completion is estimated for Mar 2028, 32 months after the start.

Of 756 non-industry interventional studies with no phase under Coronary Artery Disease, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 53. This study's planned 32 months is close to that.

Counting every sponsor, half of 933 studies reached it within 30 months; a quarter within 15 and three quarters within 50.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 4, 2025
First posted
Mar 17, 2025
StartActual
Jul 28, 2025
Primary completionEst.
Mar 31, 2028
CompletionEst.
Sep 30, 2028
Last update
Jan 2, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 2, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06878729
Lead sponsor
National Institute of Cardiology, Warsaw, Poland
Collaborators
Medical Research Agency, Poland
Responsible party
Sponsor
First posted
Mar 17, 2025
Start date
Jul 28, 2025
Primary completion
Mar 31, 2028 (estimated)
Completion
Sep 30, 2028 (estimated)
Last update
Jan 2, 2026

Study contacts

Katarzyna Istynowicz
Contact
kistynowicz@ikard.pl
0048223434268
Wioletta Antos
Contact
wantos@ikard.pl
0048223434268
Maksymilian Opolski
principal investigator · National Institute of Cardiology

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion